Granted Patent
B2
US 9,163,005 · App. 14/051,725 · Granted Oct 20, 2015
Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
Inventors:
Paul W Manley (Arlesheim, CH); Wen-Chung Shieh (Berkeley Heights, NJ); Paul Allen Sutton (Parsippany, NJ); Piotr H Karpinski (Lincoln Park, NJ); Raeann Wu (Pine Brook, NJ); Stéphanie Monnier (Raedersheim, FR); Jörg Brozio (Basel, CH)
Assignee:
Novartis AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.
Claims (1)
1. A method of treating acute lymphophatic leukemia comprising the step of administering to a subject in need thereof, a therapeutically effective amount of a salt, 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzeneamide monohydrochloride monohydrate.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 28, 2015
From: MANLEY, PAUL W; SHIEH, WEN-CHUNG; SUTTON, PAUL ALLEN; KARPINSKI, PIOTR H; WU, RAEANN; MONNIER, STEPHANIE; BROZIO, JORG
To: NOVARTIS AG
Reel/Frame 035730/0023 →
Continuity (6)
Division
11995898
Provisional Application
60701406
· Jul 20, 2005
Provisional Application
60716213
· Sep 12, 2005